Fernandez P G, Sharma J N, Galway A B, Campbell N, Kim B K, Snedden W, Granter-Button S, MacDonald J, Gill V
Curr Med Res Opin. 1982;8(2):120-7. doi: 10.1185/03007998209109767.
A double-blind study was carried out in 24 hypertensive patients with thiazide-induced hypokalaemia (serum potassium less than 3.2 mmol/l) to compare the effects of treatment with an amiloride/hydrochlorothiazide combination or hydrochlorothiazide alone. The study was divided into three phases: (i) potassium repletion (Weeks 0 to 4) with oral potassium chloride (40 mmol/day), (ii) stabilization (Weeks 4 to 6) of normokalaemia, and (iii) active drug treatment (Weeks 6 to 14), patients being allocated at random to receive one or other of the two treatments. Dosage was 2 tablets per day of the 5 mg amiloride plus 50 mg hydrochlorothiazide combination or of 50 mg hydrochlorothiazide alone. The results showed that blood pressure control was comparable in both treatment groups but hydrochlorothiazide alone caused a statistically significant reduction in serum potassium levels compared to the drug combination. Apart from 1 patient who developed hypokalaemia on hydrochlorothiazide alone, no other side-effects of treatment were reported.
对24例因噻嗪类药物导致低钾血症（血清钾低于3.2 mmol/L）的高血压患者进行了一项双盲研究，以比较使用阿米洛利/氢氯噻嗪联合用药或单独使用氢氯噻嗪治疗的效果。该研究分为三个阶段：（i）补钾阶段（第0至4周），口服氯化钾（40 mmol/天）；（ii）血钾正常稳定阶段（第4至6周）；（iii）活性药物治疗阶段（第6至14周），患者被随机分配接受两种治疗中的一种。剂量为每天2片5 mg阿米洛利加50 mg氢氯噻嗪的联合制剂或仅50 mg氢氯噻嗪。结果显示，两个治疗组的血压控制情况相当，但与联合用药相比，单独使用氢氯噻嗪导致血清钾水平出现统计学上的显著降低。除1例单独使用氢氯噻嗪出现低钾血症的患者外，未报告其他治疗副作用。
